EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)

Silmitasertib plus gemcitabine and cisplatin first‐line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study

Mitesh J Borad, Li-Yuan Bai, Donald Richards, Kabir Mody, Joleen Hubbard, Sun Young Rha, John Soong, Daniel McCormick, Emmett Tse, Daniel O'Brien, Ahmad Bayat, Daniel Ahn und 3 weitere

Hepatology · 2023-03 · 77 (3) · 760-773

DOI: 10.1002/hep.32804 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Hepatology, online erschienen am 17.02.2023. Verfasst von Mitesh J Borad und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Individualized Medicine, Liver and Biliary Cancer Research Program and Cancer Cell , Gene and Virus Therapy Lab, Mayo Clinic Arizona , Sco…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: This study aimed to investigate safety and efficacy of silmitasertib, an oral small molecule casein kinase 2 inhibitor, plus gemcitabine and cisplatin (G+C) versus G+C in locally advanced/metastatic cholangiocarcinoma. Approach and Results: This work is a Phase 1b/2 study (S4‐13‐001). In Phase 2, patients received silmitasertib 1000 mg twice daily for 10 days with G+C on Days 1 and 8 of a 21‐day cycle. Primary efficacy endpoint was progression‐free survival (PFS) in the modified intent‐to‐treat population (defined as patients who completed at least one cycle of silmitasertib without dose interruption/reduction) from both phases (silmitasertib/G+C n = 55, G+C n = 29). The response was assessed by Response Evaluation Criteria in Solid Tumors v1.1. The median PFS was 11.2 months (95% confidence interval [CI], 7.6, 14.7) versus 5.8 months (95% CI, 3.1, not evaluable [NE]) ( p = 0.0496); 10‐month PFS was 56.1% (95% CI, 38.8%, 70.2%) versus 22.2% (95% CI, 1.8%, 56.7%); and median overall survival was 17.4 months (95% CI, 13.4, 25.7) versus 14.9 months (95% CI, 9.9, NE) with silmitasertib/G+C versus G+C. Overall response rate was 34.0% versus 30.8%; the disease control rate was 86.0% versus 88.5% with silmitasertib/G+C versus G+C. Almost all silmitasertib/G+C (99%) and G+C (93%) patients reported at least one treatment emergent adverse event (TEAE). The most common TEAEs (all grades) with silmitasertib/G+C versus G+C were diarrhea (70% versus 13%), nausea (59% vs. 30%), fatigue (47% vs. 47%), vomiting (39% vs. 7%), and anemia (39% vs. 30%). Twelve patients (10%) discontinued treatment because of TEAEs during the study. Conclusions: Silmitasertib/G+C demonstrated promising preliminary evidence of efficacy for the first‐line treatment of patients with locally advanced/metastatic cholangiocarcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsHumansGemcitabineCisplatinDeoxycytidineBile Ducts, IntrahepaticAntineoplastic Combined Chemotherapy ProtocolsNaphthyridinesPhenazines

Substanzen

GemcitabineCisplatinDeoxycytidinesilmitasertibNaphthyridinesPhenazines

Autor:innen und Institutionen

  • Center for Individualized Medicine, Liver and Biliary Cancer Research Program and Cancer Cell , Gene and Virus Therapy Lab, Mayo Clinic Arizona , Scottsdale , Arizona , USA.
  • China Medical University Hospital, and China Medical University , Taichung , Taiwan.
  • Texas Oncology-Tyler, US Oncology Research , Tyler , Texas , USA.
  • Division of Hematology and Oncology , Mayo Clinic Jacksonville , Jacksonville , Florida , USA.
  • Department of Medical Oncology , Mayo Clinic Rochester , Rochester , Minnesota , USA.
  • Yonsei Cancer Center , Yonsei University College of Medicine , Seoul , South Korea.

Zitieren

APA

Borad, M. J., Bai, L. Y., Richards, D., Mody, K., Hubbard, J., Rha, S. Y., Soong, J., McCormick, D., Tse, E., O'Brien, D., Bayat, A., Ahn, D., Davis, S. L., Park, J. O., & Oh, D. Y. (2023). Silmitasertib plus gemcitabine and cisplatin first‐line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study. Hepatology, 77(3), 760-773. https://doi.org/10.1002/hep.32804

Vancouver

Borad MJ, Bai LY, Richards D, Mody K, Hubbard J, Rha SY, et al. Silmitasertib plus gemcitabine and cisplatin first‐line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study. Hepatology. 2023;77(3):760-773. doi:10.1002/hep.32804

BibTeX
@article{Borad2023,
  author = {Borad, Mitesh J and Bai, Li-Yuan and Richards, Donald and Mody, Kabir and Hubbard, Joleen and Rha, Sun Young and Soong, John and McCormick, Daniel and Tse, Emmett and O'Brien, Daniel and Bayat, Ahmad and Ahn, Daniel and Davis, S Lindsey and Park, Joon Oh and Oh, Do-Youn},
  title = {Silmitasertib plus gemcitabine and cisplatin first‐line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study},
  journal = {Hepatology},
  year = {2023},
  volume = {77},
  number = {3},
  pages = {760--773},
  doi = {10.1002/hep.32804}
}
Kostenlos starten →